--- a
+++ b/clusters/9knumclustersv2/clust_1036.txt
@@ -0,0 +1,63 @@
+Hemoglobin (Hgb) greater than . g/dL (may have packed red blood cell [PRBC] transfusion)
+Hemoglobin >  g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value
+Inability to receive HCT due to alloimmunization, defined as the inability to receive packed red blood cell (pRBC) transfusion therapy.
+Hemoglobin <  g/dL (< . mmol/L; previous red blood cell [RBC] transfusion is permitted).
+Have a hemoglobin ?. g/dL without red blood cell transfusion for ? month.
+Hemoglobin >=  g/dL (with or without packed red blood cell [PRBC] transfusion) and documented within  days prior to registration and within  days prior to the start of treatment
+Hemoglobin >. mg/dL without red blood cell transfusion ?  days prior to CD
+Hemoglobin >= . g/dL (with or without red blood cell [RBC] transfusion)
+Hemoglobin <  g/dL (< . mmol/L; previous red blood cell transfusion is permitted)
+Subjects should not have packed red blood cells (PRBC) or platelet transfusion within  days of the screening
+Hemoglobin: >= . gm/dl (may transfuse peripheral red blood cells [PRBCs])
+Hemoglobin <  g/dL (< . mmol/L; previous red blood cell [RBC] transfusion is permitted)
+Hemoglobin ?. g/dL (must be > weeks post-red blood cell transfusion)
+Within  days prior to administration of study treatment: Hemoglobin >=  g/dL with no pack red blood cell transfusion in the past  days
+Within two weeks prior to enrollment: Hemoglobin >=  gm/dL and >  days since last red blood cell transfusion
+Hemoglobin >= . g/dL (may receive packed red blood cell [prbc] transfusion)
+Within  days before the first dose of study drug: hemoglobin >  g/dL (prior red blood cell [RBC] transfusion allowed); patients may be transfused to achieve this value; elevated indirect bilirubin due to post-transfusion hemolysis is allowed
+Hemoglobin ?  g/dL (red blood cell [RBC] transfusion is allowed)
+Hemoglobin (Hgb) >=  g/dL with or without packed red blood cells (pRBC) transfusion
+Patients may be transfused with packed red blood cells (PRBCs) up to  days prior to when enrollment labs are drawn to achieve Hgb >= . mg/dL
+Platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and treatment to achieve a target plt >= ,/uL and hemoglobin of >= . g/dl, provided that patients have not received growth factors for at least  days prior to entering trial
+Hemoglobin >= . g/dL\r\n* Patients may have a transfusion of red blood cells to meet the hemoglobin requirement
+PART  GROUP  INCLUSION CRITERIA: Hemoglobin (Hgb) >=  g/dL (may receive red blood cell [RBC] transfusion)
+UROTHELIAL CARCINOMA EXPANSION COHORT: Hemoglobin >=  g/dL in the absence of packed red blood cells transfusion  days prior to dosing OR >  g/dL, if the value is constant across  readings within  weeks in the absence of packed red blood cells transfusion  days prior to dosing
+Patients must have hemoglobin >= . g/dl; platelet transfusion and packed red blood cell transfusion can also be given prior to the start of treatment and during treatment to achieve a target hemoglobin of >= ./ul provided that patients have not received growth factors for at least  days prior to entering trial
+Hemoglobin >= . mg/dL without red blood cell transfusion =<  days prior to CD
+PHASE I STUDY ELIGIBILITY CRITERIA:\r\nHemoglobin (Hgb) >=  g/dL in the absence of packed red blood cell transfusion  days prior to dosing OR Hgb -. g/dL and the value is constant across  readings within  weeks, in the absence of packed red blood cell transfusion  days prior to dosing
+PHASE II COLORECTAL CANCER COHORT  (MEDI+C ONLY):\r\nHemoglobin (Hgb) >=  g/dL in the absence of packed red blood cell transfusion  days prior to dosing
+Hemoglobin >=  g/dL (packed red blood cell [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within  days of MLA)
+Hemoglobin >=  g/dL (packed red blood cell [PRBC] transfusions permitted)
+Hemoglobin (Hgb) greater than . g/dL (may have packed red blood cell [PRBC] transfusion)
+Hemoglobin (>=) . gram per deciliter (g/dL) ([>=]  millimole per liter [mmol/L]; prior red blood cell [RBC] transfusion is permitted)
+Part : hemoglobin level of ?  g/dL within  weeks of enrollment\r\n* Packed red blood cell (PRBC) transfusions will be allowed to patients with hemoglobin < g/dl
+Hemoglobin < . g/dL (red blood cell transfusion and erythropoietin may be used to reach at least . g/dL, but must have been administered at least  weeks prior to the first dose of study drug.
+Hemoglobin >=  g/dL (packed red blood cells [PRBC] transfusions permitted)
+Hemoglobin >=  g/dL, without ongoing chronic blood transfusion or colony stimulating factor support to maintain normal levels; principal investigator approval is required; (limited red blood cell [RBC] transfusion is allowed for an acute change in hemoglobin)
+Hemoglobin >= . g/dL or >= . mmol/L, specimens must be collected within  days prior to the start of study treatment\r\n* Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last  weeks
+Hemoglobin >=  g/dl (may be after transfusion of packed red blood cells or use of erythropoiesis stimulating agents)
+Absence of a regular red blood cell transfusion requirement
+Hemoglobin >= . gm/dL (may receive packed red blood cell [PRBC] transfusions)
+Patients must not have received a transfusion (platelets or red blood cells) within  weeks of the first dose of study treatment.
+Platelet or packed red blood cell transfusion within  days of pre-treatment evaluation
+Patients who have received hematopoietic growth factor support within  days of day  of ibrutinib; patients who are Jehovahs witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patients
+Hemoglobin (Hgb) >= . g/dL (no red blood cell [RBC] transfusion within past  days)
+Hemoglobin (Hgb) >=  g/dL and no red blood cell (RBC) transfusion within the past  days prior to study registration
+Hemoglobin < g/dL (<. mmol/L; prior red blood cell [RBC] transfusion is permitted)
+Hemoglobin >=  (packed red blood cells [pRBC] transfusion +/- erythropoiesis-stimulating agents [ESA] are allowed) (must be within  days of MLA)
+Hematocrit =< % or hemoglobin =<  g/dL (but may have red blood cell [RBC] transfusion)
+Hemoglobin >=  g/dL (may have received packed red blood cell transfusion)
+Hemoglobin >=  g/dl (may transfuse packed red blood cells [PRBC] to meet parameter)
+Hemoglobin >=  g/dL; subjects may not have had a red blood cell (RBC) transfusion within  days of screening assessment
+Hemoglobin >= . mg/dL without red blood cell transfusion =<  days prior to cycle  day  of therapy
+Packed red blood cell or platelet transfusion within  days of screening laboratory tests.
+Hemoglobin >=  g/dl without packed red blood cell dependency, unless due to bone marrow involvement with lymphoma
+Hemoglobin ? . g/dL and not requiring >  unit red blood cell transfusion per month; subjects receiving therapeutic erythropoietin preparations in accordance with the FDA product label are eligible to enroll;
+Hemoglobin <  g/dL (< . mmol/L; previous red blood cell transfusion is permitted)
+Red blood cell transfusion within  weeks prior to anticipated start of study treatment.
+Anemia, Hemoglobin (Hgb) ? . g/dL or ?  units of Red Blood Cells (RBCs) within  days
+Has received a transfusion (platelets or red blood cells) within  weeks before the first dose of niraparib
+Has received a transfusion (platelets or red blood cells) within  weeks of the first dose of niraparib
+Hemoglobin ?  g/dL without red blood cell transfusion within  hours of screening.
+Hemoglobin (Hgb) >=  g/dL and no red blood cell (RBC) transfusion within the past  days prior to study registration
+Hemoglobin >= . gm/dL (may receive packed red blood cell [pRBC] transfusions)